MedNet releases updated eClinical solution

By Melissa Fassbender contact

- Last updated on GMT

MedNet releases updated eClinical solution
MedNet Solutions’ latest release of its eClinical solution, iMedNet™, features various updates that it says helps further decrease study build times.

iMedNet is a Software-as-a-Service (SaaS) clinical research technology platform that delivers Electronic Data Capture (EDC), in addition to a suite of eClinical tools to support the management and conduct of clinical trials.

According to MedNet, the new release features enhancements to various system modules, including study build tools, study revalidation tools, site record workflows, inventory, casebooks, datasets-on-demand, and reporting.

Robert Lovinger, MedNet's Senior Director of Marketing and Business Development, commented in a release, "Our focus on supporting clinical trial efficiency with a comprehensive suite of superior eClinical research tools has led to the rapid adoption of iMedNet by the global life sciences community​."

The company introduced iMedNet in 2010. As Outsourcing-Pharma.com reported​ at the time, the pay-as-you-go EDC platform supports collaboration and communication between clinical trial stakeholders.

Combining iMedNet’s industry-leading technology with its pay-as-you-go SaaS pricing model will significantly lessen the administrative burden and costs traditionally associated with EDC solutions​,” John Robertson, MedNet CEO, said at the time.

(Feature image: iStock/BrianAJackson)

Related news

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers